Breaking News Instant updates and real-time market news.

EL

Estee Lauder

$140.96

4.99 (3.67%)

, CBOE

Cboe Global Markets

$98.36

2.6 (2.72%)

09:55
08/20/18
08/20
09:55
08/20/18
09:55

Early notable gainers among liquid option names on August 20th

Notable gainers among liquid option names this morning include Estee Lauder (EL) $141.70 +5.74, CBOE Holdings (CBOE) $98.40 +2.65, CF Industries (CF) $48.84 +1.31, Allergan (AGN) $190.61 +5.00, and Kohl's (KSS) $78.46 +2.04.

EL

Estee Lauder

$140.96

4.99 (3.67%)

CBOE

Cboe Global Markets

$98.36

2.6 (2.72%)

CF

CF Industries

$48.60

1.08 (2.27%)

AGN

Allergan

$188.66

3.13 (1.69%)

KSS

Kohl's

$78.14

1.71 (2.24%)

  • 20

    Aug

  • 21

    Aug

  • 05

    Sep

  • 11

    Sep

  • 12

    Sep

EL Estee Lauder
$140.96

4.99 (3.67%)

08/16/18
PIPR
08/16/18
NO CHANGE
Target $162
PIPR
Overweight
Piper Jaffray 'positive' on Estee Lauder despite wave of negative sentiment
Piper Jaffray analyst Erinn Murphy backed an Overweight rating and $162 price target on Estee Lauder ahead of quarterly results. The analyst says she "remains positive" ahead of the August 20 Q4 report despite a growing wave of negative sentiment. While geopolitical risk remains, Murphy believe Estee Lauder's growth vectors -- China, digital, prestige, and skincare -- should support FY19 guidance that brackets the Street's estimates.
08/14/18
OPCO
08/14/18
NO CHANGE
Target $148
OPCO
Outperform
Estee Lauder price target lowered to $148 from $170 at Oppenheimer
Oppenheimer analyst Rupesh Parikh lowered his price target for Estee Lauder to $148 from $170 ahead of quarterly results. The analyst continues to look "very favorably" upon the company's long-term prospects, but expects a bumpier ride from here given prospects for slowing top and bottom-line growth and increased geopolitical uncertainty. Given the potential for less earnings upside and increased uncertainty near-term, Parikh is removing Estee Lauder as a top pick. The analyst has an Outperform rating on the shares.
07/26/18
07/26/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. PIPER CUTS 3D SYSTEMS TO UNDERWEIGHT: Piper Jaffray analyst Troy Jensen downgraded 3D Systems (DDD) to Underweight from Neutral with a $10 price target. He believes competition for the company's main product lines is intensifying. The analyst also thinks 3D will need to increase spending on direct sales, customer support and consulting, meaning "meaningful profitability" will likely be more challenged than revenue growth throughout 2018. He views the stock as overvalued. While Jensen continues to believe the overall 3D printing industry is "growing rapidly," he remains cautious on shares of 3D Systems and Stratasys (SSYS). He reiterated a Neutral rating on the latter. OPCO CUTS E.L.F. TO PERFORM: Oppenheimer analyst Rupesh Parikh downgraded e.l.f. Beauty (ELF) to Perform from Outperform saying the bull case is more uncertain from here. The analyst does not have a price target for the shares. Recent developments, including "still challenging trends" in the mass category and increased tariff uncertainty, bring greater risk to consensus forecasts, Parikh tells investors in a research note. He is harder-pressed to see the case for share outperformance. Ulta Beauty (ULTA) and Estee Lauder (EL) remain Parikh's top picks in beauty. FACEBOOK GETS MULTIPLE DOWNGRADES AFTER Q2 EARNINGS: Nomura Instinet analyst Mark Kelley downgraded Facebook (FB) to Neutral from Buy after the company delivered "underwhelming" Q2 results and guided for revenue growth deceleration through the end of the year. The revenue guidance paired with the expectation for mid-30% operating margins in the medium term or possibly longer means consensus numbers will be cut "drastically," he said. He lowered his price target on Facebook shares to $183 from $228. Facebook was also downgraded to Neutral from Buy by UBS analyst Eric Sheridan, who also lowered his price target for the shares to $180 from $212, and to Outperform from Strong Buy at Raymond James. Facebook shares are down over 19% in late morning trading. PIPER SAYS BIOGEN SELLOFF A BUYING OPPORTUNITY: Biogen (BIIB) shares "will recover and continue to work" into aducanumab's full Phase 3 data in 2020, Piper Jaffray analyst Christopher Raymond told investors. With the stock having run up into these data, the analyst said he understood the "sell-the-news" phenomenon. He believes, however, that the fundamental concerns he's heard from investors "don't seem to hold water." The analyst said to buy Biogen shares on the selloff. He kept an Overweight rating on the name with a $400 price target.
07/26/18
OPCO
07/26/18
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades e.l.f. Beauty to Perform on estimate risk
Oppenheimer analyst Rupesh Parikh downgraded e.l.f. Beauty (ELF) to Perform from Outperform saying the bull case is more uncertain from here. The analyst does not have a price target for the shares. Recent developments, including "still challenging trends" in the mass category and increased tariff uncertainty, bring greater risk to consensus forecasts, Parikh tells investors in a research note. He is harder-pressed to see the case for share outperformance. Ulta Beauty (ULTA) and Estee Lauder (EL) remain Parikh's top picks in beauty.
CBOE Cboe Global Markets
$98.36

2.6 (2.72%)

07/09/18
COMP
07/09/18
INITIATION
Target $115
COMP
Buy
Cboe Global Markets initiated with a Buy at Compass Point
Compass Point initiated Cboe Global Markets with a Buy and $115 price target.
08/20/18
RAJA
08/20/18
UPGRADE
RAJA
Outperform
Cboe Global Markets upgraded to Outperform from Market Perform at Raymond James
06/26/18
JPMS
06/26/18
UPGRADE
JPMS
Neutral
Cboe Global Markets upgraded to Neutral from Underweight at JPMorgan
06/26/18
JPMS
06/26/18
UPGRADE
Target $94
JPMS
Neutral
Cboe Global Markets upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Kenneth Worthington upgraded Cboe Global Markets to Neutral from Underweight, telling investors in a research note that he is seeing a number of signs of stabilization in both Open Interest and Volumes, though at lower levels. While he thinks estimates still have downside, the downside is more modest in the near term due to better activity levels more recently, and says he is seeing VIX futures/options activity levels reacting more positively to higher equity market volatility, a change from May and earlier in June. Worthington maintained his $94 price target.
CF CF Industries
$48.60

1.08 (2.27%)

07/18/18
RBCM
07/18/18
UPGRADE
RBCM
Sector Perform
CF Industries upgraded to Sector Perform from Underperform at RBC Capital
08/07/18
HSBC
08/07/18
UPGRADE
HSBC
Buy
CF Industries upgraded to Buy from Hold at HSBC
07/18/18
RBCM
07/18/18
UPGRADE
Target $42
RBCM
Sector Perform
CF Industries upgraded to Sector Perform at RBC Capital on energy trends
As reported earlier, RBC Capital analyst Andrew Wong upgraded CF Industries to Sector Perform from Underperform and raised his price target to $42 from $38. The analyst says the company is benefiting from the recent energy trends, with "higher oil prices pushing up the nitrogen cost curve and lower domestic natural gas prices lowering production costs". Wong adds that CF's financial position stands to improve on continued debt reduction and potential stock buybacks next year. In the mean time, the analyst expects CF Industries stock price to remain rangebound on oversupplied conditions in the nitrogen market.
06/28/18
SCOT
06/28/18
UPGRADE
SCOT
Outperform
CF Industries upgraded to Outperform from Sector Perform at Scotiabank
AGN Allergan
$188.66

3.13 (1.69%)

08/03/18
08/03/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ALLERGAN UPGRADED TO BUY: Mizuho analyst Irina Koffler upgraded Allergan (AGN) to Buy from Neutral and raised her price target for the shares to $210 from $194. The analyst views Allergan's risk/reward more favorably following the company's "strong" beat and raise quarter and the delayed introduction of Restasis generics. Allergan is up 1.2% in late morning trading. NEEDHAM UPS TRIPADVISOR TO HOLD: Needham analyst Laura Martin upgraded TripAdvisor (TRIP) to Hold from Underperform, saying that while the company's pivot to competing as an online travel agent has failed, its focus to grow its non-hotel businesses is a "higher ROI idea". FLOOR & DECOR DOWNGRADED AT JPMORGAN, PIPER: JPMorgan analyst Christopher Horvers downgraded Floor & Decor (FND) to Neutral from Overweight and lowered his price target for the shares to $45 from $59. The "story shift" taking place is likely to keep the shares in "purgatory," Horvers said following the company's Q2 results. Piper Jaffray analyst Peter Keith also downgraded Floor & Decor to Neutral and lowered his price target for the shares to $39 from $58. The analyst admitted his June upgrade of the stock was wrong following Floor & Decor's Q2 miss and guide down. Floor & Decor is down 6.4% in late morning trading. LUNA CUT TO MARKET PERFORM AT NORTHLAND: Northland analyst Tim Savageaux downgraded Luna Innovations (LUNA) to Market Perform from Outperform as he sees the shares reflecting the value of the "well executed" sale of the Opto Solutions unit at current levels. CANACCORD INITIATES TESLA WITH A HOLD: Canaccord analyst Jed Dorsheimer initiated Tesla (TSLA) with a Hold rating as he sees several risks around the company's financing, cash burn, and general maturity in the industry. Catalysts that could de-risk the shares include shifts in corporate governance, consistent production, and "a CEO who is not working 120 hours per week to hold things together," said Dorsheimer, who set a $336 price target on Tesla shares. BWS SAYS ARLO IPO ESTABLISHES VALUATION CASE FOR NETGEAR: BWS Financial analyst Hamed Khorsand said the pricing of Arlo Technologies' (ARLO) IPO establishes a valuation case for Netgear (NTGR). The analyst believes the IPO pricing gives some context to what Netgear's stake is worth and affirms his sum-of-parts reasoning for owning Netgear shares. He kept a Buy rating on the stock with a $64.50 price target.
08/03/18
08/03/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Allergan (AGN) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying she views Allergan's risk/reward more favorably following the company's "strong" beat and raise quarter and the delayed introduction of Restasis generics. 2. Pacira (PCRX) upgraded to Buy from Hold at Needham with analyst Serge Belanger citing "strong" Q2 performance of Exparel, where sales growth is accelerating while the company engages more of the anesthesiologist community. 3. Entergy (ETR) upgraded to Buy from Neutral at UBS with analyst Daniel Ford saying the stock no longer warrants a discount associated with nuclear decommissioning and operating performance risk. 4. Eversource (ES) upgraded to Neutral from Underperform at BofA/Merrill with analyst Julien Dumoulin-Smith saying the story has been de-risked with no major capex projects left. 5. TripAdvisor (TRIP) upgraded to Hold from Underperform at Needham with analyst Laura Martin saying while the company's pivot to competing as an online travel agent has failed, its focus to grow its non-hotel businesses is a "higher ROI idea." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/03/18
MZHO
08/03/18
UPGRADE
Target $210
MZHO
Buy
Allergan upgraded to Buy from Neutral at Mizuho
Mizuho analyst Irina Koffler upgraded Allergan to Buy and raised her price target for the shares to $210 from $194. The Botox maker closed yesterday up 29c to $184.28. The analyst views Allergan's risk/reward more favorably following the company's "strong" beat and raise quarter and the delayed introduction of Restasis generics. Further, the company's September 14 Aesthetics Day could drive multiple expansion in the stock, Koffler tells investors in a research note. The analyst likes Allergan's "dominance" in a growing cash pay market, low exposure to near-term rebating pressure, and improving operating margins after "unexpected" strength in the body contouring products in Q2.
08/06/18
CANT
08/06/18
NO CHANGE
Target $180
CANT
Neutral
Allergan depression drugs have billion dollar potential, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen believes Two of Allergan's depression drugs in development, rapastinel and AGN-241751, have billions of dollars in peak sales potential. These two opportunities are still underappreciated by the Street, Chen tells investors in a research note. She expects positive data for these treatments but keeps a Neutral rating on Allergan shares with a $180 price target.
KSS Kohl's
$78.14

1.71 (2.24%)

06/21/18
UBSW
06/21/18
INITIATION
Target $75
UBSW
Neutral
Kohl's initiated with a Neutral at UBS
UBS analyst Jay Sole started Kohl's with a Neutral rating and $75 price target.
06/27/18
CLVD
06/27/18
INITIATION
CLVD
Neutral
Kohl's assumed with a Neutral at Cleveland Research
Cleveland Research analyst Rusty Wilson assumed coverage on Kohl's with a Neutral saying the 2H 2018 outlook is leaning positive, offset by medium/long-term structural concerns.
08/10/18
WEDB
08/10/18
INITIATION
Target $75
WEDB
Neutral
Kohl's initiated with a Neutral at Wedbush
Wedbush analyst Jen Redding initiated Kohl's (KSS) with a Neutral rating and $75 price target, telling investors that she views Kohl's as a compelling story and sees opportunities for improvement in categories like private label, active and women's, and says Kohl's Rewards and Amazon (AMZN) pilots as potential catalysts. Longer term, Redding favors the name and sees shares of U.S.-focused retailers like Kohl's, Dillard's (DDS), Burlington Stores (BURL) and American Eagle (AEO) as good options in a year of a strong dollar.
08/20/18
DBAB
08/20/18
NO CHANGE
Target $175
DBAB
Buy
Deutsche Bank says 'sticking with' off-price, athletic brands in apparel space
Deutsche Bank analyst Paul Trussell previewed earnings for apparel companies, telling investors in a research note that he is "sticking with" off-price, the brands and athletic brands over specialty retailers and department stores. Trussell expects beats from Burlington Stores (BURL), Ross Stores (ROST), TJX (TJX), PVH (PVH), Foot Locker (FL) and Lululemon (LULU), along with American Eagle Outfitters (AEO) and Buckle (BKE) as the outliers in the specialty group and Kohl's (KSS), and says he is "a bit more cautious" for the frest of his apparel coverage given stretched valuations. Trussell raised his price target for Burlington Stores to $175 from $167, to $96 from $91 for Ross and to $105 from $100 fro TJX, but cut his price target to $171 from $176 for PVH.

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.